Chemical Structure : Bezuclastinib
CAS No.: 1616385-51-3
货号: PC-73407Not For Human Use, Lab Use Only.
Bezuclastinib (CGT9486, PLX9486) is a potent, selective tyrosine kinase inhibitor (TKI) targeting mutated KIT and demonstrating potent activity in vitro against primary exon 9 and 11 mutations, as well as secondary exon 17 and 18 mutations.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Bezuclastinib (CGT9486, PLX9486) is a potent, selective tyrosine kinase inhibitor (TKI) targeting mutated KIT and demonstrating potent activity in vitro against primary exon 9 and 11 mutations, as well as secondary exon 17 and 18 mutations.
Bezuclastinib (CGT9486, PLX9486) is a potent inhibitor of growth and KIT phosphorylation in the imatinib-sensitive and imatinib-resistant BaF3 cell lines, with growth IC50=61 nM for KIT-WT and more potently against BaF3 KIT p.D816V (IC50=6.6 nM) and BaF3 KIT p.V560G/D816V (IC50=7.1 nM).
Bezuclastinib (CGT9486, PLX9486) demonstrated signifcant tumor regression and strong inhibition of MAPK activation in imatinib-resistant GIST patient-derived xenograft (PDX) models.
分子量 | 331.379 | |
分子式 | C19H17N5O | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide |
1. Gebreyohannes YK, et al. Clin Exp Med. 2019 May;19(2):201-210.
2. Wagner AJ, et al. JAMA Oncol. 2021 Sep 1;7(9):1343-1350.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright